{
  "docId": "019dd923-622c-750b-8b9a-101b5bfde4b8",
  "docSlug": "a70fecd99534",
  "documentTitle": "Berkeley Lights (BLI)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-09-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2941177,
  "pageNumber": 4,
  "pageCount": 158,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "table_of_contents",
  "function": "front_matter",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": [
    "data_table"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-101b5bfde4b8/4",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-101b5bfde4b8",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-101b5bfde4b8.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-101b5bfde4b8#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.16
      },
      "kind": "list",
      "text": "F. Novartis ex-manager describes a farce: we got \"tricked\" and machine doesn't work; \"failed purchase\" that he wanted to return; 50% error rates; data couldn't be validated and was \"all over the place\"; too unreliable for FDA submissions; using it again would put the reputation of his current employer (a CDMO) at risk; other large customers also regret the purchase. Novartis is sixth largest player with ~$225B market cap.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4693ff9c-f251-492a-9cae-ec4967240553",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.05,
        "y": 0.66
      },
      "kind": "list",
      "text": "J. Takeda lead scientist: spent a year trying to find uses for the tool and now it's barely used; dismayed at lack of evidence/data proving its value; unusable for early stage drug discovery; negligible TAM; just an overpriced mash-up of cheap, commonplace lab tools; emerging competitors are cheaper and better. Takeda is an Asia-based pharma with $50B market cap.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54e034c2-13c0-47d4-b05c-82d165b248ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "list",
      "text": "K. Harbour Biomed ex-executive closely involved in BLI purchase says they would have sent it back for a refund if they could; 80-90% failure rate for complex antibodies; \"lot of false positives\" and errors; cost to buy and operate is out of control; BLI can't support the machine and staff seemed out of their depth. Harbour is a publicly-traded mid-tier biotech in Asia.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b45e4b4-c396-41e3-ab2f-8af25c8d4dbd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "G. AbbVie scientist who leads drug discovery teams says they have 2 machines and implies that they regret buying them; equipment mostly sit idle; portrays a disaster where 40-50% of cells are ruined during runs; 50% error rate; still \"kind of like a beta version\" despite being launched in 2016; \"major headache,\" \"tedious.\"",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91e3610c-f3ea-4646-a3b3-ddbaa6debf38",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.05,
        "y": 0.42
      },
      "kind": "list",
      "text": "H. IQVIA executive at world's largest contract research organization (CRO), with 70K employees and $50B market cap, has broad visibility into how pharma/biotech customers view BLI: key accounts are unhappy and not referenceable; BLI claims are bogus; warns IQVIA customers to stay away from BLI's tool; one of the worst vendors they rate; no traction in industry; not winning much new business.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa24b99a-9927-4a5a-aa83-7b0c3e2512cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.05,
        "y": 0.54
      },
      "kind": "list",
      "text": "I. Gilead scientist, who has 5 years of experience with the instrument at previous employers, has declined to recommend a purchase at Gilead: instrument often fails; standard assays that \"just flat out didn't work\"; key parts of value proposition are misleading and/or false; extremely small TAM; suggests BLI pipeline has dwindled in last 4-6 months. Gilead is a top 20 player with $90B market cap.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6fea338-433f-4a12-9242-f11b0dea0398",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.4,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "paragraph",
      "text": "2. Summary of findings from customer interviews (cont'd)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc9a3444-3842-4183-a39d-baee2e97264e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Novartis ex-manager describes a farce: we got \"tricked\" and machine doesn't work; \"failed purchase\" that he wanted to return — Novartis ex-manager.",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-2041-7259-a874-f06beab5f873",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Table of contents",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1652f28e-fd2b-4ca4-9613-661d5f2e4eaf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}